Cetera Investment Advisers Grows Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cetera Investment Advisers raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,362 shares of the medical equipment provider’s stock after purchasing an additional 5,004 shares during the period. Cetera Investment Advisers’ holdings in Lantheus were worth $2,768,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC increased its holdings in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 116 shares during the period. Hughes Financial Services LLC purchased a new position in Lantheus during the 1st quarter valued at about $81,000. UMB Bank n.a. increased its holdings in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 381 shares during the period. Blue Trust Inc. increased its holdings in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 633 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after purchasing an additional 298 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LNTH has been the topic of several research reports. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. B. Riley cut their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a research report on Monday, June 23rd. Truist Financial cut their price objective on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $131.20.

Lantheus Stock Performance

Shares of LNTH opened at $51.87 on Thursday. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. The business’s 50 day moving average price is $77.09 and its 200-day moving average price is $87.42. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The stock has a market cap of $3.59 billion, a P/E ratio of 14.74 and a beta of 0.14.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period in the prior year, the firm earned $1.69 earnings per share. The business’s revenue for the quarter was up .8% compared to the same quarter last year. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.